NeOnc Technologies Holdings, Inc. Common Stock

ClearOne, NeOnc Technologies, Iovance Biotherapeutics, and Ensysce Biosciences each reported significant clinical, regulatory, or financial developments. ClearOne moved closer to completing its acquisition of Cortigent, a neurotechnology subsidiary of Vivani Medical, after majority shareholder First Finance Ltd., which controls approximately 61.3% of voting power, approved the transaction and the issuance of 12.5 million shares. NeOnc Technologies is approaching topline Phase 2a data from its fully enrolled NEO100-01 study and has expanded internationally with a second IND authorization from Abu Dhabi for recurrent high-grade gliomas. Iovance Biotherapeutics reported record second-quarter 2026 revenue of approximately $99.3 million, a 66% year-over-year increase driven by its FDA-approved TIL therapy Amtagvi, and is reviewing its 2026 revenue guidance of $350 million to $370 million. Ensysce Biosciences acquired privately held Cy Biopharma, adding the clinical-stage neuroplastogenic therapy CY200 for Complex Regional Pain Syndrome Type 1, and secured financing that could total up to $77 million, including $17.1 million in cash and a $21.5 million private placement led by Ally Bridge Group.

Three biotech companies delivered distinct catalysts. NeOnc Technologies received FDA feedback on its CMC program for lead candidate NEO212, canceling a planned meeting after deeming the written responses sufficient, and expects topline Phase 2a data for NEO100 by the end of July. Ernexa Therapeutics reported independently validated preclinical results for ERNA-101, showing 67% complete tumor clearance in an ovarian cancer model when combined with anti-PD-1 therapy, ahead of a planned IND submission in the third quarter of 2026. VivoSim Labs received a $5 million milestone payment from Eli Lilly after the first patient was dosed in a Phase 2 study of a divested IBD program, and issued guidance projecting more than 500% revenue growth in Fiscal Year 2027 driven by adoption of its NAMs human tissue testing platform.

Cancer treatment is undergoing a major transformation as a new generation of biotechnology companies develops smarter, more targeted therapies. BioNTech, known for its COVID-19 vaccine, has expanded into oncology with mRNA cancer vaccines and personalized immunotherapies. Summit Therapeutics has seen success with ivonescimab, a novel immunotherapy for lung cancer. CG Oncology is working on an oncolytic immunotherapy platform for bladder cancer. NeOnc Technologies is developing targeted oncology therapies for significant unmet medical needs. These four companies represent different facets of a broader movement toward more personalized and innovative cancer care.

Several emerging companies are approaching significant inflection points. NeOnc Technologies received Investigational New Drug authorization from the Department of Health–Abu Dhabi for its NEO100 program, covering adult Phase 1 through Phase 2 studies and establishing a pathway for pediatric development in high-grade gliomas, with a Phase 2a readout expected by the end of July 2026. Boundless Bio announced a proposed merger with privately held Serapha Bio, creating a publicly traded company focused on gene-editing therapies for Alpha-1 Antitrypsin Deficiency, backed by approximately $230 million in committed financing from a syndicate led by RTW Investments and RA Capital Management. Backblaze signed a five-year, multi-exabyte data storage agreement valued at approximately $335 million with AI cloud infrastructure provider CoreWeave, positioning Backblaze as a key storage provider for portions of CoreWeave's managed storage infrastructure. HeartSciences announced a proposed business combination with Fortitude Mining Holdings, a digital asset mining platform focused primarily on Zcash, with existing Fortitude owner Digital Currency Group expected to hold approximately 95% of the combined company upon closing.

Several biotechnology companies reported significant regulatory, clinical, and commercial developments this week. NeOnc Technologies Holdings received Investigational New Drug authorization from the Department of Health – Abu Dhabi for NEO212, its oral brain tumor therapy, marking the first international regulatory clearance for the program. uniQure announced that the FDA indicated its Phase I/II data could support a Biologics License Application for accelerated approval of AMT-130 in Huntington's disease, with submission planned for the third quarter of 2026. IceCure Medical reported a 70% increase in its active U.S. commercial install base for the ProSense breast cancer cryoablation platform since receiving FDA clearance in October 2025. ClearPoint Neuro expanded its brain drug delivery ambitions through a 10-year focused ultrasound development partnership with Sungkyunkwan University in South Korea.

CervoMed shares soared more than 80% on Tuesday with key clinical trial catalysts ahead, leading a group of biotech gainers. The company's lead drug candidate Neflamapimod is in development for dementia with Lewy bodies, with a Phase 3 trial planned for the second half of 2026, and has been selected for the EXPERTS-ALS platform in the UK, with first patient dosing anticipated in the fourth quarter of 2026. Simulations Plus agreed to be acquired by affiliates of Altaris for $375 million, or $18.50 per share, a 26% premium to its 60-day volume-weighted average price. NeOnc Technologies received its first international regulatory clearance from the Department of Health - Abu Dhabi to begin a Phase 2 trial of NEO212 for aggressive brain tumors. Lunai Bioworks regained compliance with Nasdaq's minimum bid price requirement, securing its listing. Other notable movers included Conexeu Sciences, which expanded its board and appointed a chief commercial officer, and Certara, which integrated its D360 platform with Secondary Intelligence software to improve off-target safety risk evaluation.